

Claims

We claim:

1. A pharmaceutical combination comprising:
 - i) an isolated antibody molecule capable of binding to a human Programmed Death-1 (PD-1) comprising a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO: 21; a VHCDR2 amino acid sequence of SEQ ID NO: 22; and a VHCDR3 amino acid sequence of SEQ ID NO: 23; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 26, a VLCDR2 amino acid sequence of SEQ ID NO: 27, and a VLCDR3 amino acid sequence of SEQ ID NO: 28;
 - ii) an isolated antibody molecule capable of binding to macrophage colony stimulating factor 1 (M-CSF) comprising (a) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO: 3, a VHCDR2 amino acid sequence of SEQ ID NO: 4 and a VHCDR3 amino acid sequence of SEQ ID NO:5; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 6, a VLCDR2 amino acid sequence of SEQ ID NO:7 and a VLCDR3 amino acid sequence of SEQ ID NO: 8.
2. The pharmaceutical combination according to claim 1, wherein
the isolated antibody molecule capable of binding to a human Programmed Death-1 (PD-1) has a HC sequence of SEQ ID NO: 25 and a LC sequence of SEQ ID NO: 30 and
the isolated antibody molecule capable of binding to macrophage colony stimulating factor 1 (M-CSF) has a HC sequence of SEQ ID NO: 1 and a LC sequence of SEQ ID NO: 2.
3. The pharmaceutical combination according to claim 1 or 2 for use as a medicine, wherein the PD-1 antibody molecule and the M-CSF antibody molecule are administered independently at the same time or separately within time intervals.
4. The pharmaceutical combination for use according to claim 3, wherein time intervals allow the combination partners to be active.
5. The pharmaceutical combination according to claim 1 or 2 for use to treat cancer.

6. The pharmaceutical combination for use according to claim 5, wherein the cancer is triple negative breast cancer.

7. The pharmaceutical combination for use according claim 5, wherein the cancer is ovarian cancer.

8. The pharmaceutical combination for use according to claim 5, wherein the cancer is melanoma.

9. The pharmaceutical combination for use according to claim 5, wherein the cancer is pancreatic cancer.

10. The pharmaceutical combination for use according to claim 5, wherein the cancer has become resistant or refractory to PD-1 or PD-L1 therapy, wherein said cancer is TNBC or melanoma.

11. The pharmaceutical combination for use according to claim 10, wherein the PD-1 antibody molecule and the M-CSF antibody are simultaneously or sequentially administrated.

12. The pharmaceutical combination for use according to claim 10, further comprising administering a chemotherapy agent.